Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140301 | 1.00 | EGFR (0.46) | EGFRMETAP2METAP1PIK3CGHSP90AA1 | |
| SCHEMBL30446266 | 0.84 | EGFR (0.37) | EGFR | |
| SCHEMBL3234117 | 0.81 | EGFR (0.43) | EGFRMETAP2METAP1PIK3CGPIK3CD | |
| SCHEMBL30826363 | 0.77 | EGFR (0.35) | EGFR | |
| SCHEMBL29364990 | 0.77 | EGFR (0.50) | EGFRMETAP2METAP1HSP90AA1PIK3CD | |
| SCHEMBL30502330 | 0.77 | EGFR (0.50) | EGFRMETAP2METAP1HSP90AA1PIK3CD | |
| SCHEMBL12414 | 0.77 | EGFR (0.50) | EGFRMETAP2METAP1HSP90AA1PIK3CD | |
| SCHEMBL5804048 | 0.77 | EGFR (0.35) | EGFRCDC25B | |
| SCHEMBL30876200 | 0.75 | EGFR (0.48) | EGFRMETAP2METAP1HSP90AA1PIK3CD | |
| SCHEMBL11385198 | 0.75 | CCR1 (0.50) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120019059-A | Novel ACC inhibitors | 辉瑞公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119431310-A | Preparation method of obutinib and intermediate compound thereof | 北京诺诚健华医药科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4405337-A1 | FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | Beta Pharma, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-4405337-A1 | FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | Beta Pharma, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-118339146-A | Fused pyrimidine derivatives as KRAS oncoprotein inhibitors | 贝达医药公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118339146-A | Fused pyrimidine derivatives as KRAS oncoprotein inhibitors | 贝达医药公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-113637005-B | KRAS inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-3543242-C0 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2024-01-03 | — | — | EP | disclosed |
| EP-3543242-B1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023101928-A1 | FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | BETA PHARMA, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023101928-A1 | FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | BETA PHARMA, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| CN-114920738-A | KRas inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2020157487-A9 | GENETIC CONSTRUCT AND USES THEREOF | THE UNIVERSITY OF NOTTINGHAM (GB) | 2022-07-14 | — | — | WO | disclosed |